Citations

Clear

6274 citation(s) found for "To, Andrew".

Incidence and management of pleural effusions in patients with Wilms tumor: A Pediatric Surgical Oncology Research Collaborative study
Al‐Hadidi, Ameer , Rinehardt, Hannah , Sutthatarn, Pattamon , Condon, Sienna, Chen, Stephanie , Wong‐Michalak, Shannon , Short, Scott S. , Meyers, Rebecka L. , Johnston, Michael E. , Zens, Tiffany , Dasgupta, Roshni , Calabro, Kristen , Piché, Nelson , Callas, Hannah, McKay, Katlyn G. , Lovvorn, Harold N. , Tracy, Elisabeth T. , Lund, Sarah , Polites, Stephanie F. , Davidson, Jacob , Dhooma, Janel, Seemann, Natashia M. , Marquart, John , Gainer, Haley , Lal, Dave R. , Rich, Barrie S. , Glick, Richard D. , Maloney, Lauren , Radu, Stephani, Fialkowski, Elizabeth , Kwok, Pei En , Romao, Rodrigo , Newman, Erika A. , Diehl, Thomas M. , Polcz, Valerie E., Petroze, Robin T. , Aldrink, Jennifer H. , Lautz, Timothy , Lund, Sarah B, Tracy, Elisabeth T , Aldrink, Jennifer H , Dasgupta, Roshni , Talbot, Lindsay J , Murphy, Andrew J. , Whitlock, Richard S. , Naik‐Mathuria, Bindi , Utria, Alan Fremder , Rothstein, David H. , Kim, Eugene S. , Kastenberg, Zachary J. , Malek, Marcus M. , Lautz, Timothy B. , Commander, Sarah Jane , Radu, Stephanie , Rubalcava, Nathan S. , Ehrlich, Peter F. , Le, Hau D. , Stanek, Joseph

Mayo Clinic

International Journal of Cancer | June 24, 2022 | Volume: 151 | Issue: 10 | Pages: 1696-1702

10.1002/ijc.34188 | PMID 35748343 Get It

AbstractWilms tumor (WT) is the most common renal malignancy in children. Children with favorable histology WT achieve survival rates of over 90%. Twelve percent of patients present with metastatic disease, most commonly to the lungs. The presence of a pleural effusion at the time of diagnosis of WT may be noted on staging imaging; however, minimal data exist regarding the significance and prognostic importance of this finding. The objectives of our study are to identify the incidence of pleural effusions in patients with WT, and to determine the potential impact on oncologic outcomes. A multi‐institutional retrospective review was performed from January 2009 to December 2019, including children with WT and a pleural effusion on diagnostic imaging treated at Pediatric Surgical Oncology Research Collaborative (PSORC) participating institutions. Of 1259 children with a new WT diagnosis, 94 (7.5%) had a pleural effusion. Patients with a pleural effusion were older than those without (median 4.3 vs 3.5 years; P = .004), and advanced stages were more common (local stage III 85.9% vs 51.9%; P < .0001). Only 14 patients underwent a thoracentesis for fluid evaluation; 3 had cytopathologic evidence of malignant cells. Event‐free and overall survival of all children with WT and pleural effusions was 86.2% and 91.5%, respectively. The rate and significance of malignant cells present in pleural fluid is unknown due to low incidence of cytopathologic analysis in our cohort; therefore, the presence of an effusion does not appear to necessitate a change in therapy. Excellent survival can be expected with current stage‐specific treatment regimens.
Determining the time frame of maximum clinical improvement in surgical decompression for cervical spondylotic myelopathy when stratified by preoperative myelopathy severity: a cervical Quality Outcomes Database study
Berlin, Connor , Marino, Alexandria C. , Mummaneni, Praveen V. , Uribe, Juan S. , Tumialán, Luis M. , Turner, Jay D. , Wang, Michael Y. , Park, Paul , Bisson, Erica F. , Shaffrey, Mark E., Gottfried, Oren N., Than, Khoi D. , Fu, Kai-Ming, Foley, Kevin T. , Chan, Andrew K. , Bydon, Mohamad , Upadhyaya, Cheerag D., Coric, Domagoj , Asher, Anthony L. , Potts, Eric A. , Knightly, John J. , Meyer, Scott A., Buchholz, Avery L., Uribe, Juan S. , Alvi, Mohammed Ali

Mayo Clinic

Journal of Neurosurgery: Spine | June 24, 2022 | Volume: 37 | Issue: 5 | Pages: 758-766

10.3171/2022.5.spine211425 | PMID 35901760 Get It

OBJECTIVE While surgical decompression is an important treatment modality for cervical spondylotic myelopathy (CSM), it remains unclear if the severity of preoperative myelopathy status affects potential benefit from surgical intervention and when maximum postoperative improvement is expected. This investigation sought to determine if retrospective analysis of prospectively collected patient-reported outcomes (PROs) following surgery for CSM differed when stratified by preoperative myelopathy status. Secondary objectives included assessment of the minimal clinically important difference (MCID). METHODS A total of 1151 patients with CSM were prospectively enrolled from the Quality Outcomes Database at 14 US hospitals. Baseline demographics and PROs at baseline and 3 and 12 months were measured. These included the modified Japanese Orthopaedic Association (mJOA) score, Neck Disability Index (NDI), quality-adjusted life-years (QALYs) from the EQ-5D, and visual analog scale from the EQ-5D (EQ-VAS). Patients were stratified by preoperative myelopathy severity using criteria established by the AO Spine study group: mild (mJOA score 15–17), moderate (mJOA score 12–14), or severe (mJOA score < 12). Univariate analysis was used to identify demographic variables that significantly varied between myelopathy groups. Then, multivariate linear regression and linear mixed regression were used to model the effect of severity and time on PROs, respectively. RESULTS For NDI, EQ-VAS, and QALY, patients in all myelopathy cohorts achieved significant, maximal improvement at 3 months without further improvement at 12 months. For mJOA, moderate and severe myelopathy groups demonstrated significant, maximal improvement at 3 months, without further improvement at 12 months. The mild myelopathy group did not demonstrate significant change in mJOA score but did maintain and achieve higher PRO scores overall when compared with more advanced myelopathy cohorts. The MCID threshold was reached in all myelopathy cohorts at 3 months for mJOA, NDI, EQ-VAS, and QALY, with the only exception being mild myelopathy QALY at 3 months. CONCLUSIONS As assessed by statistical regression and MCID analysis, patients with cervical myelopathy experience maximal improvement in their quality of life, neck disability, myelopathy score, and overall health by 3 months after surgical decompression, regardless of their baseline myelopathy severity. An exception was seen for the mJOA score in the mild myelopathy cohort, improvement of which may have been limited by ceiling effect. The data presented here will aid surgeons in patient selection, preoperative counseling, and expected postoperative time courses.
Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt–Jakob disease and autoimmune encephalitis
Chang, Bryce Kalei , Day, Gregory S. , Graff‐Radford, Jonathan, Nguyen, Aivi T. , Toledano, Michel , Kremers, Walter K. , Petersen, Ronald C. , Chang, Bryce K , Day, Gregory S , Nguyen, Aivi T , Kremers, Walter K , Graff‐Radford, Jonathan , McKeon, Andrew , Flanagan, Eoin P. , Algeciras‐Schimnich, Alicia , Mielke, Michelle M. , Jones, David T. , Knopman, David S. , Li, Wentao

Mayo Clinic

European Journal of Neurology | June 23, 2022 | Volume: 29 | Issue: 10 | Pages: 2905-2912

10.1111/ene.15469 | PMID 35735602 Get It

AbstractBackground and purposeAutoimmune encephalitis (AE) is a potentially treatable cause of rapidly progressive dementia that may mimic Creutzfeldt–Jakob disease (CJD). Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers may discriminate CJD from AD, but utility in discriminating CJD and AE is unclear. This study compared AD CSF biomarkers in CJD and AE.MethodsPatients with probable or definite CJD and probable or definite AE who underwent Roche Elecsys AD CSF biomarker testing at Mayo Clinic from March 2020 through April 2021 were included. Total‐tau, phosphorylated181 tau and amyloid‐β42 levels were compared.ResultsOf 11 CJD cases, four were autopsy proven; the rest had positive real‐time quaking‐induced conversion testing. Disease‐associated autoantibodies were detected in 8/15 cases of AE: leucine‐rich glioma‐inactivated 1 and neuronal intermediate filaments (two cases each), and N‐methyl‐d‐aspartate receptor, contactin‐associated protein‐like 2, dipeptidyl‐peptidase‐like protein 6 and immunoglobulin‐like cell adhesion molecule IgLON family member 5. Total‐tau provided excellent discrimination between CJD and AE in a univariate model (odds ratio 1.46 per 100 pg/ml, 95% confidence interval 1.17–2.11, p < 0.05, c = 0.93). Total‐tau was elevated in 91% of CJD cases (median > 1300, range 236–>1300 pg/ml), of which 55% were above the limit of assay measurement (>1300 pg/ml). Total‐tau was elevated in 20% of AE cases (median 158, range 80–>1300 pg/ml).ConclusionTotal‐tau was greater in CJD than AE. Given that amyloid‐β42 and phosphorylated181 tau were comparable, the ratio differences were probably driven by elevated total‐tau in CJD. This study supports the role for AD biomarker testing in patients with rapidly progressive dementia.
P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM
Al‐Kali, Aref , Borate, Uma , Cluzeau, Thomas , DeZern, A. E., Kobata, Kazuma, Lyons, Roger M. , Sallman, David A. , Xiao, Zhijian , Hoef, Marlies Van, Nourry-Boulot, Claire, Sadek, Islam Mohamad, IORDAN, Ana-Maria, Sabo, Jennifer L., Garcia‐Manero, G., Zeidan, Amer M. , Esteve, Jordi , Giagounidis, Aristoteles , Platzbecker, Uwe , Santini, Valeria , Sanz, Guillermo , Sekeres, Mikkael A. , Wei, Andrew H. , Ma, Fei

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 682-683

10.1097/01.hs9.0000846032.37876.c9 Get It

The Role of Amputation and Myoelectric Prosthetic Fitting in Patients with Traumatic Brachial Plexus Injuries
Cantwell, Sean , Nelson, Andrew W. , Sampson, Brandon P. , Spinner, Robert J. , Bishop, Allen T. , Pulos, Nicholas , Shin, Alexander Y. , Cantwell, Sean R , Shin, Alexander Y , Bishop, Allen T , Pulos, Nicholas , Nelson, Andrew W.

Mayo Clinic

Journal of Bone and Joint Surgery | June 23, 2022 | Volume: 104 | Issue: 16 | Pages: 1475-1482

10.2106/jbjs.21.01261 | PMID 35976186 Get It

Background: A cohort of patients with traumatic brachial plexus injuries (BPIs) underwent elective amputation following unsuccessful surgical reconstruction or delayed presentation. The results of amputation with and without a myoelectric prosthesis (MEP) using nonintuitive controls were compared. We sought to determine the benefits of amputation, and whether fitting with an MEP was feasible and functional. Methods: We conducted a retrospective review of patients with BPI who underwent elective upper-extremity amputation at a single institution. Medical records were reviewed for demographics, injury and reconstruction details, amputation characteristics, outcomes, and complications. Prosthesis use and MEP function were assessed. The minimum follow-up for clinical outcomes was 12 months. Results: Thirty-two patients with BPI and an average follow-up of 53 months underwent elective amputation between June 2000 and June 2020. Among the cases were 18 transhumeral amputations, 12 transradial amputations, and 2 wrist disarticulations. There were 29 pan-plexus injuries, 1 partial C5-sparing pan-plexus injury, 1 lower-trunk with lateral cord injury, and 1 lower-trunk injury. Amputation occurred, on average, at 48.9 months following BPI and 36.5 months following final reconstruction. Ten patients were fitted for an MEP with electromyographic signal control from muscles not normally associated with the intended function (nonintuitive control). Average visual analog scale pain scores decreased post-amputation: from 4.8 pre-amputation to 3.3 for the MEP group and from 5.4 to 4.4 for the non-MEP group. Average scores on the Disabilities of the Arm, Shoulder and Hand questionnaire decreased post-amputation, but not significantly: from 35 to 30 for the MEP group and from 43 to 40 for the non-MEP group. Patients were more likely to be employed following amputation than they were before amputation. No patient expressed regret about undergoing amputation. All patients in the MEP group reported regular use of their prosthesis compared with 29% of patients with a traditional prosthesis. All patients in the MEP group demonstrated functional terminal grasp/release that they considered useful. Conclusions: Amputation is an effective treatment for select patients with BPI for whom surgical reconstruction is unsuccessful. Patients who underwent amputation reported decreased mechanical pain, increased employment rates, and a high rate of satisfaction following surgery. In amputees with sufficient nonintuitive electromyographic signals, MEPs allow for terminal grasp/release and are associated with high rates of prosthesis use. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
Ansell, S., Straus, David J. , Kim, W. S., Gallamini, Andrea , Ramchandren, Radhakrishnan , Friedberg, Jonathan W. , Eom, Hyeon‐Seok , Dong, C., Campana, Frank, Fenton, Keenan , Puhlmann, Markus , Hutchings, Martin , Connors, Joseph M. , Advani, Ranjana H. , Evens, Andrew M. , Smolewski, Piotr , Savage, Kerry J. , Bartlett, Nancy L. , Abramson, Jeremy S. , Radford, John

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 101-102

10.1097/01.hs9.0000843692.94815.d7 Get It

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
Foran, James M. , Tandra, A., Stefano, V. De, Mattour, Ahmad, McMullin, M. F., Rodríguez‐Macías, Gabriela , Sibai, Hassan , Qin, Qiuyue, Potluri, Jalaja , Passamonti, Francesco , Stefano, Valerio De , Fox, María Laura , Perkins, Andrew C. , How, Jeffrey

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 98-99

10.1097/01.hs9.0000843680.94912.c5 Get It

IFT80 negatively regulates osteoclast differentiation via association with Cbl-b to disrupt TRAF6 stabilization and activation
Deepak, Vishwa , Yang, Shuting , Li, Ziqing , Li, Xinhua , Ng, Andrew , Xu, Ding , Li, Yiping , Oursler, Merry Jo, Yang, Shuying , Yang, Shuying

Mayo Clinic

Proceedings of the National Academy of Sciences | June 23, 2022 | Volume: 119 | Issue: 26 | Pages: No page available

10.1073/pnas.2201490119 | PMID 35733270 Get It

Excess bone loss due to increased osteoclastogenesis is a significant clinical problem. Intraflagellar transport (IFT) proteins have been reported to regulate cell growth and differentiation. The role of IFT80, an IFT complex B protein, in osteoclasts (OCs) is completely unknown. Here, we demonstrate that deletion of IFT80 in the myeloid lineage led to increased OC formation and activity accompanied by severe bone loss in mice. IFT80 regulated OC formation by associating with Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) to promote protein stabilization and proteasomal degradation of tumor necrosis factor (TNF) receptor–associated factor 6 (TRAF6). IFT80 knockdown resulted in increased ubiquitination of Cbl-b and higher TRAF6 levels, thereby hyperactivating the receptor activator of nuclear factor-κβ (NF-κβ) ligand (RANKL) signaling axis and increased OC formation. Ectopic overexpression of IFT80 rescued osteolysis in a calvarial model of bone loss. We have thus identified a negative function of IFT80 in OCs.
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
Lassman, Andrew B. , Hoang‐Xuan, Khê , Polley, Mei‐Yin C. , Cairncross, J. Gregory , Ashby, Lynn S., Taphoorn, Martin , Souhami, Luís, Dinjens, Winand N.M. , Kouwenhoven, Mathilde C.M. , Fink, Karen, French, Pim J. , Macdonald, David R., Lacombe, Denis , Won, Minhee , Gorlia, Thierry, Bent, Martin J. van den , Taphoorn, Martin J B , Dinjens, Winand N M , Laack, Nadia N Issa , Kouwenhoven, Mathilde C M , French, Pim J , Mehta, Minesh P , van den Bent, Martin J , Brandes, Alba Ariela , Kros, Johan M. , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | June 22, 2022 | Volume: 40 | Issue: 23 | Pages: 2539-2545

10.1200/jco.21.02543 | PMID 35731991 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; P = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; P = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; P = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; P = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.
Globally accessible end-user-friendly prostate cancer risk prediction tools based on contemporary cohorts with heterogeneous missing risk factors
Neumair, Matthias, Freedland, Stephen J. , Haese, Alexander , Guerrios‐Rivera, Lourdes , Boorjian, Stephen A. , Poyet, Cédric , Herkommer, Kathleen , Meissner, Valentin H. , Kattan, Michael W. , Hoedt, Amanda M. De , Liss, Michael A. , Leach, Robin J. , Cooperberg, Matthew R , Saba, Karim , Vickers, Andrew J , Ankerst, Donna P.

Mayo Clinic

No container title available | June 22, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1716616/v1 Get It

Abstract Background: Missing risk factors, whether random or not measured at all, across different hospitals and patients provide challenges, both for the developers of online clinical risk tools and the patients trying to use such tools. This paper provides a development and end-user solution to the commonly encountered limitations of clinical risk tool based decision making due to missing information.Methods: Six state-of-the-art logistic regression approaches accommodating missing data were compared using prostate cancer data from ten North American and European cohorts from the Prostate Biopsy Collaborative Group (PBCG). An additional large European PBCG cohort was withheld for external validation, where calibration-in-the-large (CIL), calibration curves, and area-underneath-the-receiver-operating characteristic curve (AUC) were evaluated. Ten-fold leave-one-cohort-internal validation further validated the optimal missing data approach.Results: Among 12,703 biopsies from 10 training cohorts, 3,597 (28%) had clinically significant prostate cancer, compared to 1,757 of 5,540 (32%) in the external validation cohort. In external validation, the available cases method that pooled individual patient data containing all risk factors input by an end-user had best CIL, under-predicting risks as percentages by 2.9% on average, and obtained an AUC of 75.7%. Imputation had the worst CIL (-13.3%). The available cases method was further validated as optimal in internal cross-validation and thus used for development of an online risk tool. For end-users of the risk tool, two risk factors were mandatory: serum prostate-specific antigen (PSA) and age, and ten were optional: digital rectal exam, prostate volume, prior negative biopsy, 5-alpha-reductase-inhibitor use, prior PSA screen, African ancestry, Hispanic ethnicity, first-degree prostate-, breast-, and second-degree prostate-cancer family history.Conclusion: Developers of clinical risk prediction tools should optimize use of available data and sources even in the presence of high amounts of missing data and offer options for users with missing risk factors.